FDA Grants CLIA Waiver For Quidel's QuickVue(R) RSV Test

Website contains additional information and CPT billing codes...BD

Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced that the U.S. Food and Drug Administration (FDA) granted CLIA waiver for the QuickVue® RSV test for the qualitative detection of respiratory syncytial virus (RSV). The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently. The QuickVue RSV test is simple and accurate, with high sensitivity and specificity.
The test is intended for use as an aid in the diagnosis of acute respiratory syncytial viral infections